Contract manufacturing organization

WuXi STA Opens First High Potency Oral Drug Product Manufacturing Facility

Retrieved on: 
Monday, September 26, 2022

SHANGHAI, Sept. 26, 2022 /PRNewswire/ -- WuXi STA, a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the opening of its first high potency (HP) oral drug product manufacturing facility at its Wuxi city campus. This new facility marks a milestone for WuXi STA to further extend its drug product capacity and capabilities to meet the growing demand for HP drug candidate development and manufacturing services.

Key Points: 
  • SHANGHAI, Sept. 26, 2022 /PRNewswire/ -- WuXi STA, a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the opening of its first high potency (HP) oral drug product manufacturing facility at its Wuxi city campus.
  • With this new facility, WuXi STA is well positioned to provide an integrated R&D and manufacturing network for high potency active pharmaceutical ingredients (HPAPI) and drug product from preclinical to commercial manufacturing.
  • Dr. Minzhang Chen, Co-CEO of WuXi AppTec and CEO of WuXi STA, commented, "We are delighted to announce the opening of our first drug product manufacturing facility for high potency oral products.
  • Last year, WuXi STA established its first Europe-based drug product manufacturing facility in Couvet, Switzerland, which provides tablet & capsule commercial manufacturing and packaging capabilities.

WuXi STA Opens a New Sterile Lipid Nanoparticle Formulation Facility to Enhance Global CRDMO Services for Customers

Retrieved on: 
Friday, September 9, 2022

SHANGHAI, Sept. 9, 2022 /PRNewswire/ --WuXi STA, a subsidiary of WuXi AppTec, today announced the opening of a new sterile lipid nanoparticle (LNP) formulation development and manufacturing facility at its Wuxi city campus.

Key Points: 
  • SHANGHAI, Sept. 9, 2022 /PRNewswire/ --WuXi STA, a subsidiary of WuXi AppTec, today announced the opening of a new sterile lipid nanoparticle (LNP) formulation development and manufacturing facility at its Wuxi city campus.
  • WuXi STA has 12 sites across the U.S., Europe and Asia that offer a wide range of services and meet global regulatory standards.
  • Together with other development and manufacturing sites, this new platform provides considerable synergy with the company's oligonucleotide CRDMO platform.
  • WuXi STA (stapharma.com), a subsidiary of WuXi AppTec, is a leading pharmaceutical development and manufacturing capability and technology platform company serving the life sciences industry, with global operations.

WuXi STA Breaks Ground for New Pharmaceutical Manufacturing Facility in Middletown, Delaware

Retrieved on: 
Tuesday, August 16, 2022

MIDDLETOWN, Del., Aug. 16, 2022 /PRNewswire/ -- WuXi STA, a leading Contract Research, Development, and Manufacturing Organization (CRDMO), is pleased to announce the groundbreaking for its new 190-acre pharmaceutical manufacturing campus in Middletown, Delaware.

Key Points: 
  • MIDDLETOWN, Del., Aug. 16, 2022 /PRNewswire/ -- WuXi STA, a leading Contract Research, Development, and Manufacturing Organization (CRDMO), is pleased to announce the groundbreaking for its new 190-acre pharmaceutical manufacturing campus in Middletown, Delaware.
  • "Over the next five years, WuXi STA plans to build a state-of-the-art pharmaceutical manufacturing campus in one of Delaware's fastest-growing communities, bringing with it good jobs and economic growth.
  • "Today's groundbreaking of the WuXi STA pharmaceutical manufacturing plant represents another step in that spirit of innovation bringing good-paying jobs to Middletown and strengthening communities throughout Delaware.
  • WuXi STA (stapharma.com), a subsidiary of WuXi AppTec (wuxiapptec.com), is a leading pharmaceutical development and manufacturing capability and technology platform company serving the life sciences industry, with global operations.

U.S. Government Orders Another 2.5 Million Doses of Monkeypox Vaccines from Bavarian Nordic

Retrieved on: 
Friday, July 15, 2022

The new order follows two previous orders from BARDA in June and July 2022 for 500,000 and 2.5 million doses respectively which, together with an order from BARDA in 2020 for 1.4 million doses, will bring the total deliveries in 2022 and 2023 to nearly 7 million doses.

Key Points: 
  • The new order follows two previous orders from BARDA in June and July 2022 for 500,000 and 2.5 million doses respectively which, together with an order from BARDA in 2020 for 1.4 million doses, will bring the total deliveries in 2022 and 2023 to nearly 7 million doses.
  • Paul Chaplin, President and CEO of Bavarian Nordic said: Expanding our manufacturing capabilities into the United States allows Bavarian Nordic to deliver more monkeypox vaccines to meet the immediate worldwide demand for JYNNEOS.
  • Under this contract Bavarian Nordic has produced bulk vaccine, corresponding to approximately 13 million doses for future delivery.
  • Bavarian Nordic is a fully integrated vaccines company focused on the development, manufacturing and commercialization of life-saving vaccines.

WuXi STA Opens New Large-scale Oligonucleotide and Peptide Manufacturing Facility

Retrieved on: 
Thursday, July 7, 2022

SHANGHAI , July 6, 2022 /PRNewswire/ -- WuXi STA, a subsidiary of WuXi AppTec, today announced the opening of a new large-scale oligonucleotide and peptide manufacturing facility at its Changzhou campus. The new facility underscores WuXi STA's ongoing commitment to enhance its capacity and capability to meet the fast-growing customer needs for oligonucleotide and peptide therapeutics development and manufacturing worldwide, making more innovative therapies accessible to the patients. 

Key Points: 
  • SHANGHAI, July 6, 2022 /PRNewswire/ -- WuXi STA, a subsidiary of WuXi AppTec, today announced the opening of a new large-scale oligonucleotide and peptide manufacturing facility at its Changzhou campus.
  • The new facility underscores WuXi STA's ongoing commitment to enhance its capacity and capability to meet the fast-growing customer needs for oligonucleotide and peptide therapeutics development and manufacturing worldwide,making more innovative therapies accessible to the patients.
  • oligonucleotide plant, WuXi STA extends its leadership in oligonucleotide development and manufacturing worldwide, with four large-scale oligonucleotide production lines and more than 20 small- to mid-scale production lines that increase the overall manufacturing capacity of a single synthesis run from 1.9 mol to 6.0 mol.
  • In addition, WuXi STA offers injectable formulation development and manufacturing services, including Lipid NanoParticle technology (LNP), as well as comprehensive analytical and Chemical, Manufacturing, and Controls (CMC) dossier preparation services, which further accelerate the development of new oligonucleotide and peptide therapeutics for the market.

U.S. Government Orders Additional Monkeypox Vaccines from Bavarian Nordic

Retrieved on: 
Friday, July 1, 2022

The doses will be manufactured from bulk vaccine already manufactured and invoiced under previous contracts with BARDA and currently stored at Bavarian Nordic.

Key Points: 
  • The doses will be manufactured from bulk vaccine already manufactured and invoiced under previous contracts with BARDA and currently stored at Bavarian Nordic.
  • Under this contract Bavarian Nordic has produced bulk vaccine, corresponding to approximately 13 million doses for future delivery.
  • Bavarian Nordic is a fully integrated vaccines company focused on the development, manufacturing and commercialization of life-saving vaccines.
  • The vaccine is also approved for protection against smallpox and monkeypox in Canada, and as a smallpox vaccine in Europe.

HOOKIPA Announces Executive Leadership Changes

Retrieved on: 
Tuesday, June 21, 2022

NEW YORK and VIENNA, Austria, June 21, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, HOOKIPA), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced several leadership changes as the company expands its clinical development and pipeline programs.

Key Points: 
  • NEW YORK and VIENNA, Austria, June 21, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, HOOKIPA), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced several leadership changes as the company expands its clinical development and pipeline programs.
  • In her new role, Schlienger becomes a member of the Executive Team and will lead all clinical development programs for HOOKIPA globally, inclusive of immuno- oncology and infectious diseases.
  • Prior to joining HOOKIPA, Necina was Senior Vice President and Chief Strategist at Takeda and a member of the companys R&D Pharmaceutical Science Leadership Team.
  • In addition, HOOKIPA aims to develop functional cures of HBV and HIV in collaboration with Gilead.

Jubilant HollisterStier LLC enters into cooperative agreement of $149.6 Mn with US Government to expand critical vaccine manufacturing capacity

Retrieved on: 
Monday, May 30, 2022

Speaking on the announcement, Pramod Yadav, CEO, Jubilant Pharma Limited said,"Jubilant HollisterStier LLC is committed to making the US pharmaceutical supply chain more resilient with domestic manufacturing facilities and less reliant on foreign suppliers.

Key Points: 
  • Speaking on the announcement, Pramod Yadav, CEO, Jubilant Pharma Limited said,"Jubilant HollisterStier LLC is committed to making the US pharmaceutical supply chain more resilient with domestic manufacturing facilities and less reliant on foreign suppliers.
  • We are proud to support the US government in their efforts of making the US more prepared and ready for future pandemics."
  • Jubilant HollisterStier LLC, a subsidiary of Jubilant Pharma Limited, is a leading integrated contract manufacturer of sterile injectables, ophthalmics, optics, sterile and non-sterile topicals and liquids.
  • With facilities in North America, Jubilant HollisterStier LLC provides specialized manufacturing for the pharmaceutical and biopharmaceutical industries.

Jubilant HollisterStier LLC enters into cooperative agreement of $149.6 Mn with US Government to expand critical vaccine manufacturing capacity

Retrieved on: 
Monday, May 30, 2022

Speaking on the announcement, Pramod Yadav, CEO, Jubilant Pharma Limited said,"Jubilant HollisterStier LLC is committed to making the US pharmaceutical supply chain more resilient with domestic manufacturing facilities and less reliant on foreign suppliers.

Key Points: 
  • Speaking on the announcement, Pramod Yadav, CEO, Jubilant Pharma Limited said,"Jubilant HollisterStier LLC is committed to making the US pharmaceutical supply chain more resilient with domestic manufacturing facilities and less reliant on foreign suppliers.
  • We are proud to support the US government in their efforts of making the US more prepared and ready for future pandemics."
  • Jubilant HollisterStier LLC, a subsidiary of Jubilant Pharma Limited, is a leading integrated contract manufacturer of sterile injectables, ophthalmics, optics, sterile and non-sterile topicals and liquids.
  • With facilities in North America, Jubilant HollisterStier LLC provides specialized manufacturing for the pharmaceutical and biopharmaceutical industries.

Societal CDMO Secures Manufacturing and Packaging Task Order Award from National Cancer Institute (NCI)

Retrieved on: 
Wednesday, April 27, 2022

SAN DIEGO and GAINESVILLE, Ga., April 27, 2022 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (Societal CDMO; NASD: SCTL ), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced that it has been awarded a new manufacturing and packaging task order agreement by the National Cancer Institutes Division of Cancer Treatment and Diagnosis (DCTD).

Key Points: 
  • SAN DIEGO and GAINESVILLE, Ga., April 27, 2022 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (Societal CDMO; NASD: SCTL ), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced that it has been awarded a new manufacturing and packaging task order agreement by the National Cancer Institutes Division of Cancer Treatment and Diagnosis (DCTD).
  • Under terms of the new task order award, Societal CDMO will develop and provide DCTD with a scalable manufacturing and packaging process for cGMP production of 100 mg ATTM capsules.
  • The content of this press release is solely the responsibility of Societal CDMO and does not necessarily represent the official views of the National Cancer Institute.
  • With an expertise in solving complex manufacturing problems, Societal CDMO is a leading CDMO providing therapeutic development, end-to-end regulatory support, clinical and commercial manufacturing, aseptic fill/finish, lyophilization, packaging and logistics services to the global pharmaceutical market.